US EditionCancer-Causing Contaminant in Blood Pressure Pills May Point to Higher Safety Risks in Older Generic Drugs
The FDA recalled over 580,000 capsules of Teva's prazosin for elevated nitrosamines, which may cause cancer if ingested long-term, officials said.
6 Articles
6 Articles
Cancer-causing contaminant in blood pressure pills may point to higher safety risks in older generic drugs
A generic blood pressure drug called prazosin, made by Teva Pharmaceuticals, is being recalled by the Food and Drug Administration because it contains elevated levels of cancer-causing chemicals called nitrosamines.
FDA Recalls Common Blood Pressure Drug For Cancer-Causing Chemicals
A generic blood pressure drug called prazosin, made by Teva Pharmaceuticals, is being recalled by the Food and Drug Administration because it contains elevated levels of cancer-causing chemicals called nitrosamines.
What to know about the FDA's recall of the blood pressure drug prazosin
A generic blood pressure drug called prazosin, made by Teva Pharmaceuticals, is being recalled by the Food and Drug Administration because it contains elevated levels of cancer-causing chemicals called nitrosamines.
FDA recall of blood pressure pills due to cancer-causing contaminant may point to higher safety risks in older generic drugs
by C. Michael White, University of Connecticut, [This article first appeared in The Conversation, republished with permission] A generic blood pressure drug called prazosin, made by Teva Pharmaceuticals, is being recalled by the Food and Drug Administration because it contains elevated levels of cancer-causing chemicals called nitrosamines. The recall, which Teva announced on Oct. 7, 2025, affects more than 580,000 prazosin capsules. Prazosin is…
The U.S. Food and Drug Agency orders the withdrawal of a generic treatment to regulate blood pressure. Prazosin, manufactured by the Teva Pharmaceuticals laboratory, contains high concentrations of nitrosamines: chemical compounds known for their carcinogenic properties. The announcement of the recall dates back to 7 October 2025 and concerns more than 580 ... Read more The article FDA withdraws from the market a drug against hypertension contam…
RWJBarnabas, SciTech Scity test digital blood pressure patch
The basics: RWJBarnabas Health, SciTech Scity partner on digital health pilot Biobeat‘s FDA-cleared cuffless patch enables 24-hour BP monitoring Pilot launched at Jersey City Medical Center for hypertension patients Program aims to improve access, accuracy and equity in health care A pilot program between RWJBarnabas Health and the Liberty Science Center‘s SciTech Scity Healthcare Innovation Engine is showing the vast potential of digital healt…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
